IPGaia, Inc., (“IPG”) and University of California San Diego (“UC San Diego”), based in La Jolla, California, USA, have entered into a Master Collaborative Research and Development Agreement (“this agreement”) dated July 1st, 2022. This agreement establishes a formal framework for the incorporation of promising drug target leads from UC San Diego into IPG’s drug discovery platform. Following UC San Diego’s strong history of partnering with industry to advance drug discovery, the program enables UC San Diego to propose drug targets to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. For patients, personalized medicine holds great …
Notice of Company Name Change and New President & CEO Assume Office
IP Generator, Inc. (Headquarter: Minato Tokyo, President & CEO: Satoru Iino) will change its name to the following as of July 1, 2022, to further strengthen its business foundation with a new management team. 1. Company Name Change New company name：IPGaia, Inc. (Hereinafter, “IPG”) Background ：”Gaia” is a primordial god that has existed since the beginning of the world in ancient Greek mythology. We have decided to name our company “IP Gaia” with the passion to contribute to society by improving medical access and reducing medical costs as a drug discovery platformer that efficiently generates high-quality clinical development candidates from drug seeds, which is a new beginning in Japan. 2. …
Continue reading “Notice of Company Name Change and New President & CEO Assume Office”
IP Generator, Inc. and RIKEN Announce Drug Discovery Alliance Agreement
IP Generator, Inc., (“IPG”) and National Research and Development Institute, RIKEN (“RIKEN”), based in Saitama, Japan, have entered into a Drug Discovery Alliance Agreement (“this agreement”) dated June 3, 2022. This agreement, executed with the support of RIKEN Innovation Co., Ltd. (RIKEN Innovation), establishes a formal framework for the incorporation of promising drug target leads from RIKEN into IPG’s drug discovery platform. The program enables RIKEN to propose drug seeds to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. IPG aims for the efficient creation of innovative medicines and hopes to contribute to solving global social issues …
Continue reading “IP Generator, Inc. and RIKEN Announce Drug Discovery Alliance Agreement”